HRP20030853B1 - Crystalline form of omeprazole - Google Patents

Crystalline form of omeprazole

Info

Publication number
HRP20030853B1
HRP20030853B1 HR20030853A HRP20030853A HRP20030853B1 HR P20030853 B1 HRP20030853 B1 HR P20030853B1 HR 20030853 A HR20030853 A HR 20030853A HR P20030853 A HRP20030853 A HR P20030853A HR P20030853 B1 HRP20030853 B1 HR P20030853B1
Authority
HR
Croatia
Prior art keywords
omeprazole
crystalline form
powder
values
ray diffraction
Prior art date
Application number
HR20030853A
Other languages
English (en)
Croatian (hr)
Inventor
Hafner Mila�
Eopar Anton
Podobnik Barbara
Cizerle Bel�i�
Kosak Alenka
Ornik Brina
Urleb Uro�
Original Assignee
Lek Pharmaceutical And Chemical Company D.D. Legal Affairs And Industrial Property Dept.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030853(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceutical And Chemical Company D.D. Legal Affairs And Industrial Property Dept. filed Critical Lek Pharmaceutical And Chemical Company D.D. Legal Affairs And Industrial Property Dept.
Publication of HRP20030853A2 publication Critical patent/HRP20030853A2/xx
Publication of HRP20030853B1 publication Critical patent/HRP20030853B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20030853A 2001-04-25 2003-10-20 Crystalline form of omeprazole HRP20030853B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100111A SI20875A (sl) 2001-04-25 2001-04-25 Kristalna oblika omeprazola
PCT/IB2002/001350 WO2002085889A1 (en) 2001-04-25 2002-04-24 Crystalline form of omeprazole

Publications (2)

Publication Number Publication Date
HRP20030853A2 HRP20030853A2 (en) 2005-08-31
HRP20030853B1 true HRP20030853B1 (en) 2011-11-30

Family

ID=20432882

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030853A HRP20030853B1 (en) 2001-04-25 2003-10-20 Crystalline form of omeprazole

Country Status (26)

Country Link
US (2) US20040122056A1 (sl)
EP (1) EP1390360B1 (sl)
JP (1) JP4455815B2 (sl)
KR (1) KR20030094358A (sl)
CN (1) CN1531533B (sl)
AT (1) ATE346063T1 (sl)
AU (1) AU2002307892B2 (sl)
BG (1) BG108287A (sl)
BR (1) BR0209103A (sl)
CA (1) CA2445251C (sl)
CZ (1) CZ20032911A3 (sl)
DE (1) DE60216273T2 (sl)
HR (1) HRP20030853B1 (sl)
HU (1) HUP0303928A2 (sl)
IL (1) IL158561A0 (sl)
MX (1) MXPA03009789A (sl)
NO (1) NO20034715L (sl)
NZ (1) NZ528917A (sl)
PL (1) PL366471A1 (sl)
RS (1) RS50880B (sl)
RU (1) RU2286991C2 (sl)
SI (2) SI20875A (sl)
SK (1) SK13192003A3 (sl)
UA (1) UA77671C2 (sl)
WO (1) WO2002085889A1 (sl)
ZA (1) ZA200307988B (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
EP1988163B1 (en) * 2006-02-22 2012-06-27 International Institute of Cancer Immunology, Inc. Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN102786513A (zh) * 2011-05-18 2012-11-21 中国医学科学院药物研究所 奥美拉唑晶e型物质及制备方法与在药品和保健品中应用
CN102351846B (zh) * 2011-09-07 2012-08-22 周晓东 一种新的奥美拉唑钠化合物及其药物组合物
KR101459088B1 (ko) * 2012-08-02 2014-12-02 대화제약 주식회사 알-라베프라졸, 이의 금속염의 제조방법
WO2023079094A1 (en) * 2021-11-05 2023-05-11 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005129A1 (en) * 1978-04-14 1979-10-31 Aktiebolaget Hässle Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation
WO1998028294A1 (en) * 1996-12-20 1998-07-02 Astra Aktiebolag A novel compound form
WO1999008500A2 (en) * 1998-11-10 1999-02-25 Astrazeneca Ab New crystalline form of omeprazole
WO2002000876A1 (en) * 2000-06-28 2002-01-03 Commonwealth Scientific And Industrial Research Organisation Truncated egf receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE67187B1 (en) * 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005129A1 (en) * 1978-04-14 1979-10-31 Aktiebolaget Hässle Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation
WO1998028294A1 (en) * 1996-12-20 1998-07-02 Astra Aktiebolag A novel compound form
WO1999008500A2 (en) * 1998-11-10 1999-02-25 Astrazeneca Ab New crystalline form of omeprazole
WO2002000876A1 (en) * 2000-06-28 2002-01-03 Commonwealth Scientific And Industrial Research Organisation Truncated egf receptor

Also Published As

Publication number Publication date
BR0209103A (pt) 2004-07-13
UA77671C2 (en) 2007-01-15
SI1390360T1 (sl) 2007-04-30
CA2445251C (en) 2011-01-04
CN1531533B (zh) 2012-07-18
SI20875A (sl) 2002-10-31
JP2004526786A (ja) 2004-09-02
AU2002307892B2 (en) 2008-04-17
EP1390360A1 (en) 2004-02-25
US20060079560A1 (en) 2006-04-13
EP1390360B1 (en) 2006-11-22
PL366471A1 (en) 2005-02-07
DE60216273T2 (de) 2007-05-31
BG108287A (bg) 2005-04-30
RU2003133213A (ru) 2005-05-10
ZA200307988B (en) 2004-10-14
US20040122056A1 (en) 2004-06-24
KR20030094358A (ko) 2003-12-11
IL158561A0 (en) 2004-05-12
SK13192003A3 (sk) 2004-03-02
CA2445251A1 (en) 2002-10-31
JP4455815B2 (ja) 2010-04-21
ATE346063T1 (de) 2006-12-15
MXPA03009789A (es) 2005-03-07
NO20034715D0 (no) 2003-10-21
HRP20030853A2 (en) 2005-08-31
US7553856B2 (en) 2009-06-30
DE60216273D1 (de) 2007-01-04
NZ528917A (en) 2006-02-24
NO20034715L (no) 2003-12-10
WO2002085889A1 (en) 2002-10-31
HUP0303928A2 (hu) 2004-03-01
CZ20032911A3 (en) 2004-06-16
RS50880B (sr) 2010-08-31
CN1531533A (zh) 2004-09-22
YU84003A (sh) 2006-08-17
RU2286991C2 (ru) 2006-11-10

Similar Documents

Publication Publication Date Title
HRP20030853B1 (en) Crystalline form of omeprazole
IL158485A0 (en) Spiropyrazole compounds
DE60135387D1 (de) 7,9 substituierte tetracyclinverbindungen
AP1537A (en) A crystalline form of perindopril tert-butylamine salt.
DE60229736D1 (de) Spiroinden- und spiroindan-verbindungen
WO2002012166A3 (en) Triamine derivative melanocortin receptor ligands and methods of using same
ATE338035T1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
HK1075839A1 (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-pyrrole mono-hydrochloride
GEP20074165B (en) Imidazolopyridines and methods of making and using the same
IS2571B (is) Munntökuform af própívíríni, þannig útbúið að hinum virka þætti er sleppt út á löngum tíma
GB0124627D0 (en) Novel compounds
MY134354A (en) Wireless network access point configuration
HRP20030154B1 (en) Preparation of risperidone
HRP20010117B1 (en) Novel salt form of pantoprazole
DK1975164T3 (da) Octahydrobenzimidazolon-forbindelser som analgetika
SI1279665T1 (sl) Postopek za pripravo perindoprila, njegovih analogov in njegovih soli, z uporabo 2,5-diokso-oksazolidin-intermediatnih spojin
MXPA05006450A (es) Nuevo derivado de 2,4-diamino-1,3,5-triazina.
JP2001354766A5 (sl)
DK1347984T3 (da) Fremgangsmåde til fremstilling af taxanderivater
MXPA02012400A (es) Heterociclos hetaril-substituidos.
ZA200603660B (en) Novel 2,4-diamino-1,3,5-triazine derivative
DK1090915T3 (da) Polymorphic B form af 3-(cyclopropylmethoxy)-4--4-(methylsulfonyl)phenyl- 5,5-dimethyl-5H-furan-2-on
EA200400263A1 (ru) Способ получения аморфной формы торсемида
PL364495A1 (en) The use of 2$g(a),3$g(a),17ss-trihydroxy-5$g(a)-androstan-6-one as active ingredient for plant development regulation
DE50214487D1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190401

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200330

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210420

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20220424